

## Gefitinib (Iressa) in Non-Small Cell Lung Cancer: A Retrospective Analysis

Karim Rashid<sup>1</sup>, Zaber Otrock<sup>1</sup>, Ahmad Husari<sup>1</sup>, Marwan Ghosn<sup>2</sup>, Joseph Kattan<sup>2</sup>, Nagi S. El-Saghir<sup>1</sup>, Nizar Bitar<sup>3</sup>, Ghazi Nsouli<sup>4</sup>, Walid Moukaddem<sup>5</sup>, Georges Chabine<sup>2</sup>, Ziad Salem<sup>1</sup>, Ali Shamseddine<sup>1</sup>.

(1) American University of Beirut Medical Center, Beirut, Lebanon;

(2) Hotel-Dieu de France, University Hospital, Beirut, Lebanon;

(3) Sabel Hospital, Beirut, Lebanon;

(4) Makassed Hospital, Beirut, Lebanon;

(5) Islamic Hospital, Tripoli, Lebanon

PAJO, June 2008, 1(2): 8-10

### Abstract

**Background** This study is a retrospective review of 50 non-small cell lung cancer (NSCLC) patients who received 250 mg/day gefitinib (Iressa) as third-line monotherapy.

**Patients and Methods** 50 patients were included in this study. The data were collected from five tertiary care centers in Lebanon.

**Results** The mean age of patients was 61 (median 64); 72% were male and 28% female. All 50 patients received 250 mg oral gefitinib as monotherapy for a mean duration of 3.9 months (range 1-19 months). One-year and three year survival was 73% and 21% respectively. Patients with Eastern Cooperative Oncology Group (ECOG) status 0-1 as compared to patients with ECOG status 2-4 enjoyed significantly better survival and response rates.

**Conclusion** From the data it appears that patients may benefit from earlier administration of gefitinib